U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C21H27NO3
Molecular Weight 341.444
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-816336

SMILES

OC1CN(C1)C(=O)CC2(C3CC4CC2CC(C3)C4O)C5=CC=CC=C5

InChI

InChIKey=OAAZMUGLOXGVNH-UHFFFAOYSA-N
InChI=1S/C21H27NO3/c23-18-11-22(12-18)19(24)10-21(15-4-2-1-3-5-15)16-6-13-7-17(21)9-14(8-16)20(13)25/h1-5,13-14,16-18,20,23,25H,6-12H2

HIDE SMILES / InChI

Molecular Formula C21H27NO3
Molecular Weight 341.444
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Tue Apr 01 16:52:37 GMT 2025
Edited
by admin
on Tue Apr 01 16:52:37 GMT 2025
Record UNII
HLF8J24L87
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-816336
Common Name English
1-(3-HYDROXYAZETIDIN-1-YL)-2-(6-HYDROXY-2-PHENYL-2-ADAMANTYL)ETHANONE
Preferred Name English
ETHANONE, 1-(3-HYDROXY-1-AZETIDINYL)-2-(6-HYDROXY-2-PHENYLTRICYCLO(3.3.1.13,7)DEC-2-YL)-
Systematic Name English
Code System Code Type Description
FDA UNII
HLF8J24L87
Created by admin on Tue Apr 01 16:52:37 GMT 2025 , Edited by admin on Tue Apr 01 16:52:37 GMT 2025
PRIMARY
CLINICAL_TRIALS.GOV
BMS-816336
Created by admin on Tue Apr 01 16:52:37 GMT 2025 , Edited by admin on Tue Apr 01 16:52:37 GMT 2025
PRIMARY Official Title: Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects;Purpose: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.
CAS
1009583-20-3
Created by admin on Tue Apr 01 16:52:37 GMT 2025 , Edited by admin on Tue Apr 01 16:52:37 GMT 2025
PRIMARY
PUBCHEM
59336911
Created by admin on Tue Apr 01 16:52:37 GMT 2025 , Edited by admin on Tue Apr 01 16:52:37 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Compounds 7 and 8 (Scheme 1) are two 11-.BETA.-hsd1 inhibitors synthesized and investigated at Bristol-Myers Squibb.4 The synthesis of both 7 and 8 required the introduction of the adamantanol hydroxyl group with the desired stereochemistry.Many ketoreductases are commercially available, and this activity is very common in microbial strains. This paper describes screening to identify ketoreductases with the desired stereospecificity, initial preparation of the chiral alcohols with a commercial ketoreductase, and purification, cloning and expression of a more effective ketoreductase from Candida utilis ATCC 42181.